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Abstract 
 
Hematopoietic stem cell transplantation (HSCT) is be-
coming an increasingly popular treatment considering 
that it is the only curative option for many malignant 
and non-malignant diseases. Many patients treated in 
this way have been followed for two or three decades 
post-transplant and are presumed to be cured. But, on 
the other hand, a great proportion of these patients are 
experiencing long-term side effects after HSCT, inclu-
ding non-malignant organ or tissue dysfunction, chan-
ges in quality of life, infections and secondary malignan-
cy. Renal complications caused by HSCT are high and 
are associated with the development of both acute and 
chronic kidney failure. So, considering the increasing 
numbers of HSCT survivors many years after the trans-
plantation, chronic kidney disease due to HSCT is be-
coming a growing problem and represents a new po-
pulation of patients who are presented to nephrologists. 
The three most common forms of chronic kidney di-
sease related to HSCT are: chronic calcineurin nephro-
toxicity, glomerular disease after HSCT and HSCT asso-
ciated thrombotic microangiopathy. 
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Case presentation 
 
In January 2013 a 21-year-old man was admitted to the 
Department of Nephrology after experiencing pedal and 
facial edema for the last 14 days. His medical history be-
gan in 2007 when he was diagnosed with acute lympho-
blastic leukemia (ALL). He underwent chemotherapy 
according to the ALL-IC-BFM 2002. After an apparent 
remission, three years later he presented with isolated 
medullary relapse. He received treatment with the ALL-
REZ BFM protocol that led to cytomorphological remi-
ssion. The patient underwent myeloablative allogenic 
peripheral stem cell transplantation with his HLA-iden-
tical sister as the donor. The conditioning regimen con-
sisted of cyclophosphamide and 12-Gy total-body irra-
diation. The patient received cyclosporine and methotre-
xate for graft-versus-host disease (GVHD) prophylaxis. 
He responded well and continued further ambulatory 
monitoring by a hematologist. There was no sign of 
residual ALL on follow-up.  
Results of his physical examination showed periorbital 
and pretibial edema. Renal function was normal; with a 
serum creatinine level of 80 µmol/L. He had proteinuria 
with protein of 9 g/24h. The kidney ultrasound was 
normal. He underwent a percutaneous renal biopsy that 
showed membranous nephropathy. Further hematology-
cal investigation showed no signs of ALL relapse. 
 
Introduction 
 
Hematopoietic stem cell transplantation (HSCT) is be-
coming an increasingly popular treatment considering 
that it is the only curative option for many malignant 
and non-malignant diseases [1]. In general, HSCT con-
sists of three steps. In the first phase, patients are 
given preconditioning regimen which consists of total-
body irradiation and/or chemotherapy. The decision 
whether to perform myeloablative or nonmyeloablative 
conditioning regimen depends on the patient age, co-
morbid states, the underlying disease and the disease 
stage. Myeloablative regimens may be associated with 
high morbidity during the cytopenic period, and for this 
reason this approach is reserved for younger patients 
without co-morbid conditions.  In the second step, the 
patient receives an infusion consisting of bone marrow, 
peripheral-blood, or umbilical cord progenitor cells 
which are derived from either a donor (and then we are 
talking about allogeneic HSCT) or the patients them-
selves (autologous HSCT). In the third step immuno-
suppressive medications are used in order to decrease 
the risk of graft-versus-host disease (GVHD). These 
are usually methotrexate or the calcineurin inhibitors 
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(CNIs) cyclosporine or tacrolimus. Using the mentioned 
approach many patients have now been followed for 
two or three decades post-transplant and are presumed 
to be cured [1,2]. On the other hand, a great proportion 
of these patients are experiencing long-term side 
effects after HSCT, including non-malignant organ or 
tissue dysfunction, changes in quality of life, infections 
and secondary malignancy [3]. Rates of renal complica-
tions caused by HSCT have been reported as high as 
92% and are associated with the development of both 
acute and chronic kidney failure [4]. The risk factors for 
kidney injury following HSCT vary depending on the 
types of regimens that are used in patients undergoing 
HSCT. Namely, a high-dose conditioning regimen is used 
in both myeloablative allogeneic and autologous HSCT 
and frequently in combination with high dose radiothe-
rapy. Furthermore, myeloablative allogeneic HSCT also 
requires the use of immunosuppressive therapy post-
transplant, most of the time with calcineurin inhibitors 
and this is not necessary in autologous HSCT [2,5]. 
Recently, a newly developed form of HSCT, a non-
myeloablative or reduced-intensity conditioning (RIC) 
allogeneic HSCT is being used in older patients or in 
those with co-morbid medical conditions. With this pro-
cedure patients receive a lower dose of chemoradiothe-
rapy, but post-transplant immunosuppression therapy 
is also required. The intensity of the conditioning regi-
men, especially the use of full-dose myeloablative total 
body irradiation (TBI) is more likely to cause late 
complications after allo-HSCT. On the other hand, it has 
been well-established that the use of RIC can reduce short-
term acute toxicity, but it has also been well-documen-
ted that the probability of chronic graft-host-versus 
disease (cGHVD) is not reduced after implementation 
of this regimen, namely because this approach is used 
in older patients and in more advanced disease stages 
[1,6-8].  These observations are supported by the study 
of Al Hazzouri, as well [9]). In the aforementioned 
analysis the authors have investigated the appearance 
of chronic kidney disease (CKD) in patients that have 
received RIC versus myeloablative regimens, and they 
observed that there were no significant differences in 
terms of renal complications between two patients’ 
groups. According to this observation and considering 
the increasing incidence of HSCT related nephropathy, 
the aim of this review is to provide an update on the 
recent knowledge in the approach to patients with 
suspected HSCT nephropathy. 
 
Acute kidney injury (AKI) after HSCT 
 
The incidence of AKI in the days and weeks following 
myeloablative regimens varies from 30% to 90%. It is 
significantly higher in patients receiving an allogenic 
HSCT, and approximately 33% of these patients require 
renal replacement therapy (RRT) (10). Mortality is 2 to 
7 times higher in patients experiencing AKI compared 
to those without AKI, and when those patients require 
RRT, the mortality rates may eventually rise to more 
than 80%, mainly due to association with coexistent 
injury of multiple organs [11,12]. Also, the important 
risk factor that may be driving the sustained rates of 
AKI is patients’ age at the time of transplantation, 
which is steadily increasing. The fastest growing group 
of patients who undergo HSCT includes patients over 
the age of 60. It has already been well-established that 
age is a risk factor for AKI. Acute kidney injury follo-
wing HSCT is related to prerenal (such as fluid deple-
tion, sepsis, drugs…), intrinsic renal (acute tubular 
necrosis due to ischemia, nephrotoxic drugs, acute 
interstitial nephritis, infection-associated kidney injury 
and vascular disorders) and postrenal (intratubular or 
extratubular obstruction) causes [2]. During the first 
month after HSCT the main predisposing factors for 
development of AKI are: sepsis, nephrotoxic drugs, 
obstruction, tumor lysis syndrome, hepatorenal syndro-
me from veno-occlusive disease, acute thrombocytope-
nic purpura or hemolytic uremic syndrome (TTP/HUS), 
acute graft-host-versus disease (aGHVD) and cytome-
galovirus (CMV) reactivation. Veno-occlusive disease 
(VOD) usually develops within 30 days after HSCT 
with the incidence of approximately 10% for allogenic 
HSCT, and with lower incidence rate for autologous 
HSCT. VOD is also known as sinusoidal obstruction 
syndrome, and is a conditioning-related toxicity usually 
associated with regimens including cyclophosphamide, 
busulfan, and/or total body irradiation. Clinically, it is 
characterized by an acute onset of jaundice, ascites 
and painful hepatomegaly followed by azotemia, low 
urine sodium excretion and with bland urine. The 
severity of the disease varies. In mild to moderate 
cause hepatic injury is self-limited, but this condition 
can progress to multi-organ failure (MOF) [2,11,13].  
Tumor lysis syndrome is characterized by hyperkale-
mia, hyperuricemia, hyperphosphatemia, and hypocal-
cemia. Acute graft-host-versus disease (aGHVD) is the 
most frequent complication following allogenic HSCT 
and it usually occurs within the time frame of two weeks 
up to three months after transplantation and aGHVD 
causes renal injury that ranges from prerenal azotemia to 
thrombotic thrombocytopenic purpura-like microangio-
pathy [2]. TTP-like microangiopathy has a poor respon-
se to treatment with apheresis and is accompanied by 
a mortality rate up to 60%. When approaching a 
patient with AKI following HSCT, it's important to 
differentiate the cause of renal failure. According to 
this, management of AKI ranges from adequate use of 
fluids, antibiotics, avoidance of nephrotoxic agents, use 
of dialysis, etc. Treatment of hepatorenal syndrome 
due to veno-occlusive disease in these cases is mainly 
supportive [13]. Treatment of TTP/HUS because of the 
applied specific therapy primarily involves avoidance 
of the aforementioned medications. Management of  
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other types of TTP/HUS demands implementation of 
plasma exchanges and/or eculizumab [2]. There is no 
convincing data to support the efficiency of plasma 
exchange in patients who develop thrombotic microan-
giopathy after HSCT. This is in contrast to the well-
known beneficial effect seen in most other forms of TTP-
HUS. This might be partially explained by the fact that 
TTP-HUS following HSCT occurs due to direct injury to 
the kidney from nephrotoxic drugs and/or radiation. Treat-
ment of tumor lysis syndrome consists of identifying 
those patients that are at risk, careful laboratory moni-
toring and the use of prophylactic therapy (hydration, 
urine alkalinization and use of xanthine oxidase inhi-
bitors). Acute renal failure due to tumor lysis syndrome 
often requires some dialysis treatment (hemodialysis 
and/or hemofiltration) [14-16]. 
 
Chronic kidney disease (CKD) after HSCT 
 
Within six months of transplantation some of the pa-
tients who undergo HSCT develop chronic kidney di-
sease (CKD). The incidence of CKD related to HSCT 
varies worldwide and depends on the used diagnostic 
criteria, definition of CKD, duration of follow-up, and 
the type of HSCT. When we include all these factors 
the incidence of CKD related to HSCT ranges from 15% 
to as high as 60%. The growth in non-myeloablative 
protocols may actually increase the incidence of CKD in 
patients undergoing HSCT despite its milder conditioning 
regimen, because of older patients’ age and increased base-
line co-morbidities in this population of patients [2,17-18]. 
Independent risk factors for development of CKD in-
clude AKI in the first 100 days, previous autologous 
HSCT, CNI use, and chronic GVHD [2]. 
The three most common forms of CKD related to 
HSCT are: chronic CNI nephrotoxicity, glomerular disease 
after HSCT (chronic GVHD-associated glomerulo-
nephritis), and HSCT associated thrombotic microan-
giopathy (TA-TMA) [2]. 
 
Chronic CNI nephrotoxicity 
 
Calcineurin inhibitors, mainly cyclosporine and tacro-
limus, can cause renal injury similar to that seen in other 
settings, such as solid organ transplantation. These are 
used to prevent GVHD in the period of several months 
after allogenic HSCT. This approach is associated with 
a 25% incidence of moderate to severe aGVHD. Accor-
ding to these observations, patients who require prolon-
ged therapy for GVHD will receive these medications 
for a longer period of time and are at great risk of de-
veloping side-effects, mainly nephrotoxicity. The main 
pathohistological findings are non-specific and include 
obliterative arteriolopathy, afferent arteriolar hyalinosis, 
and patchy interstitial fibrosis [2,19-20]. 
 
 
HSCT associated thrombotic microangiopathy  
(TA-TMA) 
 
Transplant-associated thrombotic microangiopathy (TA- 
TMA) is a severe complication of HSCT, and usually 
occurs within 6 to 12 months after transplantation. The 
kidney is the most commonly affected organ, but in 
some cases it may present as a systemic condition, with 
high mortality rate, while in milder cases there is an in-
creased risk of a resulting chronic kidney disease [2,21-23]. 
Published studies have shown discrepant results in the 
incidence rates of TA-TMA, ranging from 0.5% to 76% 
which is mainly due to diagnostic uncertainty, and limi-
ted prospective data. According to the most large, retro-
spective studies, the incidence rate of TA-TMA is about 
10-25%, which more likely represents the true burden of 
the disease [2,24]. 
The pathogenesis of thrombotic microangiopathy after 
HSCT is still poorly understood but it is believed that the 
most important setting in the pathogenesis of TA-TMA is 
the endothelial injury in the context of HSCT. Namely, it 
is believed that during the first six months after transplan-
tation various etiological factors cause endothelium inj-
ury, which leads to endothelial inflammation. Further-
more, dysregulation of interaction between platelets and 
damaged endothelium results in thrombosis and fibrin 
deposition in the microcirculation, which in turn causes 
end-organ damage [2]. The most important risk factors 
for development of TA-TMA are: irradiation and che-
motherapy, mainly the use of cyclophosphamide, busul-
fan, cisplatin and carmustine [24,25]. Radiotherapy is 
performed as a total-body irradiation or radio- immu-
notherapy or both treatments are implemented. TA-TMA 
is more common after allogeneic HSCT, but it can de-
velop in patients who undergo autologous transplanta-
tion. Both myeloablative and reduced intensity condi-
tioning regimens are risk factors for developing TA-
TMA. Recent investigations have failed to produce a 
statistical difference in the prevalence of TA-TMA bet-
ween reduced intensity and myeloablative conditioning 
regimens. Furthermore, it is known that partial renal 
shielding during total body irradiation may reduce the 
risk of TA-TMA development [2,25-27]. 
It is also believed that several other conditions may con-
tribute to the development of TA-TMA, such as: sclero-
derma, pregnancy-related kidney disease, malignancy, 
numerous medications and infections (most commonly 
Aspergillus, cytomegalovirus, and adenovirus). It remains 
unclear if other potential infections (parvovirus B19, 
human herpes virus-6, and BK virus infection) play a 
role in the development of TA-TMA even though there 
has been a great interest in their role. It is important to 
emphasize that TA-TMA can occur in the presence or 
absence of GVHD, and with or without a triggering 
infection [28-30]. 
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However, considering the complexity of the HSCT po-
pulation, it's doubtful that a single etiological factor is 
responsible for the development of TA-TMA in all 
affected patients and it is more likely that TA-TMA is a 
consequence of several etiological factors that lead to 
endothelial injury of the kidney and other organs in the 
setting of HSCT. This hypothesis is supported by the 
fact that classic thrombotic microangiopathies have been 
successfully linked to a single etiology, such as Shiga 
toxin in diarrhea-positive HUS. According to these ob-
servations, TA-TMA was first thought to be TTP but as 
TA-TMA did not respond as well to plasma exchange 
as TTP did, this condition was distinct from "classic" 
TTP/HUS [5]. This might be partially explained by the 
fact that TTP-HUS following HSCT occurs because of 
direct injury to the kidney from nephrotoxic drugs and/ 
or radiation. Furthermore, it is believed that deficiency 
of the ADAMTS-13 protease, present in classic TTP, is 
not involved in the pathogenesis of thrombotic microan-
giopathy following HSCT [2,23,24]. 
The pathohistological features of TA-TMA in the kid-
ney are non-specific and include thickened capillary 
walls, fragmented erythrocytes, occluded vascular lu-
mens, and endothelial separation accompanied by swe-
lling, fibrin deposition, and necrosis [2,33]. As mentioned 
above, in contrast to patients with "classic" TTP, patients 
with TA-TMA have rarely been reported to have sys-
temic thromboses, although recent case reports have 
presented the involvement of other organs, namely 
the lungs [32] and the gastrointestinal tract [33]. 
Characteristic clinical features include slowly rising 
plasma creatinine, hypertension, and disproportionate 
anemia, but some patients are experiencing a more 
fulminant presentation. It is important to say that hy-
pertension is more likely due to CNI-nephrotoxicity. 
Proteinuria, usually in the absence of persistent hypo-
albuminemia, is an important sign of renal involve-
ment in TA-TMA. Also, urinalysis shows variable hema-
turia, depending on the extent of kidney involvement. 
In some patients, chronic TA-TMA presents as a low-
grade microangiopathic hemolysis with the usual la-
boratory findings such as intermittent or persistent ele-
vation in plasma lactate-dehydrogenase level, low serum 
haptoglobin level, anemia, thrombocytopenia, and pre-
sence of schistocytes in the peripheral blood [2,16,-
23,24]. Furthermore, in patients with kidney-limited TMA, 
the characteristic laboratory findings are missing, and hence 
a kidney biopsy is necessary in these patients [2]. 
Treatment of TA-TMA includes medical management 
and withdrawal of promoting medications, mainly CNIs 
and cisplatin. However, medical approach includes the 
use of antihypertensive drugs, use of recombinant eryt-
hropoietin, red blood cell transfusions, and plasma ex-
change. Preclinical studies indicate a beneficial effect 
of the angiotensin converting enzyme inhibitors (ACEI) 
in the treatment of HSCT-related TMA. Although the 
use of ACEI has not been utilized in patients with TA-
TMA, it seems reasonable to believe that patients with 
persistent proteinuria after HSCT could benefit from 
this therapy. Further prospective studies are needed 
to confirm their beneficial effect [2,15,16]. 
The effectiveness of plasma exchange in the treatment 
of TA-TMA is unclear, and according to most studies 
patients who have undergone this treatment had poor 
response and high mortality rate [34]. 
According to some studies, the use of new drugs, such 
as daclizumab, rituximab, defibrotide, and eicosapentae-
noic acid could be useful in the treatment of HSCT-
related TMA [2,35-37]. 
Another therapeutic approach to patients with ESRD 
due to HSCT is kidney transplantation. In the last deca-
de numerous cases of successful kidney transplantta-
tion in these patients have been published [2]. 
In the absence of controlled trials that evaluate addi-
tional treatment modalities in patients with HSCT-re-
lated TMA, for now, discontinuation of offending agents 
may be the most promising therapeutic option com-
pared to other treatment modalities.  
 
Glomerular disease after HSCT 
 
Nephrotic syndrome (NS) is a well-documented but 
rare complication after HSCT. It is mainly related to 
membranous nephropathy and occurs in about 75% 
of all cases of HSCT-associated NS [38,39]. It is less 
frequently related to minimal change disease, focal 
segmental glomerulonephrosis, diffuse proliferative 
glomerulonephritis or IgA nephropathy. Post-HSCT 
NS is characterized with immune-complex deposits, and 
mainly represents the consequence of GVHD. Namely, 
most patients with HSCT-related NS have other mani-
festations of cGVHD at the time of diagnosis. Accor-
ding to some authors this condition could represent the 
renal manifestation of cGVHD. This hypothesis is su-
pported by the fact that NS usually occurs late in the 
course of transplantation when the patient is off immu-
nosuppressive therapy [2,4,39-42]. 
It is also important to say that in adult subjects NS 
may represent the manifestation of different malignancy 
states, and the appearance of NS is an absolute indica-
tion for renal biopsy. It is necessary to exclude a clinical 
relapse of primary disease in HSCT patients, as well [4].  
Treatment of HSCT-related NS is controversial, and in 
the absence of randomized controlled trials, the current 
therapeutic options mostly include use of cyclosporine 
(CSA) and corticosteroids (CS). In the majority of stu-
dies patients were treated with a high-dose steroid the-
rapy (starting dose was 1 mg/kg, and the duration of 
treatment ranged from 2 months to a year) in order to 
reduce NS. Furthermore, in most cases the use of an 
additional immunosuppressive drug was necessary. Cyc-
losporine was the most commonly used additional drug. 
The duration of treatment with CSA varies from 6 to 12 
months. Other immunosuppressive drugs that are repor-
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ted in the setting of HSCT-related NS were mycophe-
nolate, azathioprine, and cyclophosphamide. TNF blo-
ckers have showed a limited success, but there are pro-
mising results with the use of anti-CD 20 antibody, 
such as rituximab. According to these observations, the 
current approach in the treatment of HSTC-related NS 
should include the use of CSA and CS in order to con-
trol the acute manifestations of cGVHD. This is nece-
ssary as a prerequisite to the remission of NS [39-42].  
 
Approaching the patients with HSCT-related 
chronic kidney disease 
 
Patient’s history important notes include the type of 
HSCT, the used conditioning regimen and the use of 
nephrotoxic drugs, mainly CNIs. General treatment should 
be recommended for any CKD patient. In a patient with a 
TA- TMA due to HSCT the hypertension control is nece-
ssary in order to reduce endothelial damage. Further-
more, patients with persistent proteinuria after HSCT 
could benefit from the use of ACEI. Hyperkalemia may 
be more common in HSCT patients than in patients 
with other forms of CKD. Diuretics are often needed. 
Considering the toxicity of CNIs, it is worthwhile to 
minimize their dosage or to replace them with other 
agents, such as m-TOR inhibitors, sirolimus or evero-
limus. According to some investigations, GVHD prophy-
laxis with sirolimus and mycophenolate mofetil has been 
found to be promising alternative therapy to CNIs [2,4].  
A subset of patients progress to ESRD, and overall 
patients who undergo hemodialysis have worse survi-
val rates than patients with ESRD due to other etiolo-
gical factors. Renal transplantation is treatment option 
in some patients, especially in those who receive a renal-
allograft from the same donor as their original HSCT, 
considering the fact that this approach may obviate the 
need for antirejection therapy because of the immunoto-
lerance of the allograft [5,4,33]. 
  
 
      Fig. 1. Shematic view of the disease course in our patient 
     * acute lymphoblastic leukemia (ALL); graft-versus-host disease (GVHD); chronic graft-versus-host disease (cGVHD) 
 
Case review 
 
In line with the findings of kidney biopsy, nephrotic 
syndrome associated with membranous nephrophaty 
was diagnosed, probably due to cGVHD. The treatment 
of the patient started with an oral dose of ramipril 1.25 
mg per day. This led to an improvement of hypertension 
and proteinuria. The patient was discharged from our 
Department and referred to the Hematological Depart-
ment because of the need for further immunosuppressi-
ve therapy in order to control cGVHD (Figure 1). 
 
Conclusions 
 
Hematopoietic stem cell transplantation offers a curative 
treatment for many malignant and non-malignant di 
sorders. A wide spectrum of renal involvement can be 
observed in these patients. Considering the increasing 
number of HSCT survivors many years after transplant-
tation, especially older patients with co-morbidities, 
long-term complications such as CKD and ESRD rep-
resent a growing problem. Renal biopsies are often 
needed to identify the underlying cause of renal failure 
in HSCT patients. According to this, once the under-
lying pathology is known, an appropriate therapeutic 
approach can be used in order to prevent progression to 
ESRD. There is a need for further research in this field 
in order to better define the natural history and clinical 
features of HSCT-related kidney injury and the treat-
ment of this relatively new entity. 
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